IPO Details

Bidding Dates

21 Jun '24 - 25 Jun '24

Minimum Investment

₹136,000/1 Lot ( 4000 Shares )

Price Range

₹32 to ₹34

Maximum Investment

₹136,000/1 Lot ( 4000 Shares )

Retail Discount

To be announced

Issue Size

₹10.54 Cr

Investor category and sub category

Qualified Institutional Buyers  |   Retail Individual Investors  |   Non-institutional Investors  |   Eligible Employees and Eligible Shareholders  |  

Medicamen Organics Limited IPO Important Dates

Important dates with respect to IPO allotment and listing

Opening Date

Jun 21, 2024

Closing Date

Jun 25, 2024

Allotment Date

Jun 26, 2024

Initiation of Refunds

Jun 27, 2024

Credit of Shares to Demat

Jun 27, 2024

Listing Date

Jun 28, 2024

Cut-off time for UPI mandate confirmation

Jun 25, 2024

About Medicamen Organics Limited

Medicamen Organics Limited is involved in developing, manufacturing, and distributing a broad range of pharmaceutical dosages. These include generic forms such as tablets, capsules, oral liquids, ointments, gels, syrups, suspensions, and dry powders. The company serves both state and central government institutions as well as private entities, acting as a contract or third-party manufacturer. Products are marketed to private pharmaceutical companies domestically and internationally through third-party distributors or on a loan license basis. Recently, the company has focused on establishing a direct international presence, exemplified by direct exports to Burundi in fiscal 2023 and 2024.

Operating under a B2B model, Medicamen Organics partners with various pharmaceutical companies for contract manufacturing. The company's products are distributed across India and regions including Africa, the CIS, and Southeast Asia, covering countries like Congo, Benin, Togo, Senegal, the Philippines, Myanmar, and Kenya. The company boasts two WHO GMP-approved manufacturing facilities in Haridwar, Uttarakhand, spanning 21,536 square feet, with comprehensive quality control departments and in-house testing laboratories. Certified to ISO 9001:2015, the company emphasises product development and research, contributing to a diverse product portfolio of 84 drugs, including antibiotics, anti-diabetics, and multivitamins.

Consistent quality and compliance with safety standards are central to Medicamen Organics' operations. The company continuously seeks to expand its product line with complementary offerings. A professional management team led by promoters and directors with nearly three decades of industry experience oversees operations. 

Medicamen Organics follows a contract manufacturing business model, partnering with pharmaceutical companies that market and sell the products. By March 31, 2024, the company had 84 product registrations and partnerships with 44 domestic and 12 international entities. Additionally, the company participates in government tenders, supplying products to various government institutions and leveraging advantages such as bulk orders and committed volumes. Key product categories include capsules, ointments, suspensions, dry powder sachets, and tablets.

Industry Outlook:

  1. The growth of the Indian pharmaceutical market to USD 130 billion by 2030 presents substantial opportunities for Medicamen Organics Limited to expand its product offerings and market reach.
  2. India supplies 20% of global generic drugs and 60% of vaccines, underscoring its critical role in global healthcare. As India maintains its status as a major supplier of generics and vaccines, Medicamen Organics Limited can leverage this position to enhance its export footprint and enter new international markets.
  3. The sector has attracted significant foreign direct investment (FDI), with FDI inflows reaching USD 21.46 billion by March 2023. The FDI inflow and supportive government policies can facilitate Medicamen Organics Limited's securing funding for expansion, innovation, and capacity building, driving future growth and competitiveness.

Medicamen Organics Limited IPO Objectives 

The company plans to allocate the net proceeds from the issuance to the following purposes:

  1. Allocate up to ₹300 lakhs for registering products in international markets.
  2. Spend up to ₹225 lakhs to update the plant and increase production capacity.
  3. Utilise up to ₹400 lakhs to meet working capital requirements.
  4. Utilise remaining funds for general corporate purposes.

Peer Details

The following are the listed industry peers of Medicamen Organics Limited:

  1. Brooks Laboratories Limited
  2. Cian Healthcare Limited
  3. Zenotech Laboratories Limited

How to Check the Allotment Status of the Medicamen Organics Limited IPO?

Steps to check IPO allotment status on Angel One’s app:

  • Log in to the Angel One app
  • Go to the individual order details page of the IPO that you had applied for. 
  • Check the IPO allotment status. As such, Angel One will notify you of your IPO allotment status via push notification, email, and SMS.

Contact Details of Medicamen Organics Limited

Registered office: 10 Community Centre No 2 Ashok Vihar Phase II, New

Delhi, Delhi, 110052, India.

Email:  cs@mediorganics.in

Phone: +91-9818222845

IPO Financials

Particulars Year ending on 31st March, 2024 Year ending on March 31, 2023 Year ending on March 31, 2022
Revenue from Operations (in ₹ lakh) 2527.17 2,214.71 2,097.52
Profit After Tax (PAT) (in ₹ lakh) 240.41 96.93 10.14
Cash & Cash Equivalents (in ₹ lakh) 55.30 52.82 43.74
Return on Net Worth (%) 15.83 10.79 1.27
Earnings Per Share (“EPS”) (%) 3.18 1.62 0.17
EBITDA(in ₹ lakh) 475.56 268.37 140.85
Return On Capital Employed (%) 14.50 9.50 3.99

Know before investing


  1. The company offers 84 diverse pharmaceutical products, including tablets, capsules, and syrups.

  2. Medicamen Organics Limited's facilities are WHO GMP-approved and ISO 9001:2015 certified.

  3. The company maintains good relations with distributors and receives repeat orders.

  4. The company aims to enhance its global presence by registering more products.

  5. The company intends to increase direct exports to improve profit margins and sales.

  6. The company has a presence in India and multiple international markets.


  1. Approval delays for licenses and permits could negatively impact business operations and growth.

  2. Raw material price fluctuations could affect margins and profitability.

  3. Dependence on key customers risks significant revenue reduction.

  4. Reliance on major suppliers could disrupt business operations.

  5. Non-compliance penalties harm financial health and reputation.

  6. Lease termination could adversely impact business operations.

  7. Unregistered trademarks risk business value and reputation.

  • How to Apply in IPO
  • How to Check IPO Allotment Status

Login to Angel One App / Website & click on IPO

Select desired IPO & tap on "Apply"

Enter UPI ID, set quantity/price & submit

Accept mandate on the UPI app to complete the process

Login to Angel One App / Website

Choose IPO section on Home Page

Click IPO Orders

Chose the IPO application you want to view the status for

Medicamen Organics Limited IPO FAQs

What is Medicamen Organics Limited's IPO?

Medicamen Organics Limited IPO is a book built issue IPO. The IPO will be open from June 21, 2024, to June 25, 2024.

When will Medicamen Organics Limited's IPO be allotted?

The Basis of Allotment will happen on Wednesday, June 26, 2024.

When will Medicamen Organics Limited's IPO open for subscription?

The IPO subscription window will open on June 21, 2024.

What minimum lot size can retail investors subscribe to?

The lot size for Medicamen Organics Limited’s IPO is 1 lot of 4000 shares, with a minimum investment of ₹136,000.

When will Medicamen Organics Limited list on exchanges?

The listing date for Medicamen Organics Limited is June 28, 2024.

How do I check the allotment status of the Medicamen Organics Limited IPO?

Steps to check IPO allotment status on Angel One’s app:

  • Log in to the Angel One app
  • Go to the individual order details page of the IPO that you had applied for. 
  • Check the IPO allotment status as such, Angel One will notify you of your IPO allotment status via push notification, email and SMS.

What would be the listing gains on the Medicamen Organics Limited IPO?

Listing gains cannot be ascertained before the listing of the IPO on the stock exchange.

I have finished the application process for the Medicamen Organics Limited IPO, but the funds still need to be debited. What is the reason?

Initially, the bank will only block the amount in your account. The money will not be debited until the stocks are allotted to you.

How do I approve the UPI mandate request for Medicamen Organics Limited IPO?

You must complete the payment process by logging in to your UPI handle and approving the payment mandate.

Can I submit more than one application for the public issue of Medicamen Organics Limited using one PAN?

You can submit only one application using your PAN card.